Limits...
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.

Coriat R, Gouya H, Mir O, Ropert S, Vignaux O, Chaussade S, Sogni P, Pol S, Blanchet B, Legmann P, Goldwasser F - PLoS ONE (2011)

Bottom Line: All patients under sorafenib therapy had a decrease in portal venous flow of at least 36%.In contrast, no specific change was observed in the azygos vein or the abdominal aorta.Sorafenib is the first anti-angiogenic therapy to demonstrate a beneficial and reversible decrease of portal venous flow among cirrhotic patients.

View Article: PubMed Central - PubMed

Affiliation: Center for Research on Angiogenesis Inhibitors (CERIA), Hôpital Cochin, AP-HP, Paris, France. romain.coriat@cch.aphp.fr

ABSTRACT
Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to determine the effect of sorafenib on portal venous flow and portosystemic collateral circulation in patients receiving sorafenib therapy for advanced hepatocellular carcinoma. Porto-collateral circulations were evaluated using a magnetic resonance technique prior sorafenib therapy, and at day 30. All patients under sorafenib therapy had a decrease in portal venous flow of at least 36%. In contrast, no specific change was observed in the azygos vein or the abdominal aorta. No portal venous flow modification was observed in the control group. Sorafenib is the first anti-angiogenic therapy to demonstrate a beneficial and reversible decrease of portal venous flow among cirrhotic patients.

Show MeSH

Related in: MedlinePlus

Modification of Blood flow measured on Magnetic Resonance Imaging under sorafenib therapy and after withdrawal.(a) Portal Venous flow, (b) Azygos Venous flow, and (c) Abdominal Aortic Flow.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3038868&req=5

pone-0016978-g002: Modification of Blood flow measured on Magnetic Resonance Imaging under sorafenib therapy and after withdrawal.(a) Portal Venous flow, (b) Azygos Venous flow, and (c) Abdominal Aortic Flow.

Mentions: At baseline, all patients had portal venous blood flow, values consistent with those observed in control group or previously described in cirrhotic patients (Table 2). [25] Patients from control group had no modification of porto-collateral circulations during the period of monitoring while patients under sorafenib therapy had a decrease in portal venous flow of at least 36% (Fig. 2a). At withdrawal, portal venous flow seeks to recover values before sorafenib. In contrast, no specific change was observed in the azygos vein or the abdominal aorta (Fig. 2b, c).


Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.

Coriat R, Gouya H, Mir O, Ropert S, Vignaux O, Chaussade S, Sogni P, Pol S, Blanchet B, Legmann P, Goldwasser F - PLoS ONE (2011)

Modification of Blood flow measured on Magnetic Resonance Imaging under sorafenib therapy and after withdrawal.(a) Portal Venous flow, (b) Azygos Venous flow, and (c) Abdominal Aortic Flow.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3038868&req=5

pone-0016978-g002: Modification of Blood flow measured on Magnetic Resonance Imaging under sorafenib therapy and after withdrawal.(a) Portal Venous flow, (b) Azygos Venous flow, and (c) Abdominal Aortic Flow.
Mentions: At baseline, all patients had portal venous blood flow, values consistent with those observed in control group or previously described in cirrhotic patients (Table 2). [25] Patients from control group had no modification of porto-collateral circulations during the period of monitoring while patients under sorafenib therapy had a decrease in portal venous flow of at least 36% (Fig. 2a). At withdrawal, portal venous flow seeks to recover values before sorafenib. In contrast, no specific change was observed in the azygos vein or the abdominal aorta (Fig. 2b, c).

Bottom Line: All patients under sorafenib therapy had a decrease in portal venous flow of at least 36%.In contrast, no specific change was observed in the azygos vein or the abdominal aorta.Sorafenib is the first anti-angiogenic therapy to demonstrate a beneficial and reversible decrease of portal venous flow among cirrhotic patients.

View Article: PubMed Central - PubMed

Affiliation: Center for Research on Angiogenesis Inhibitors (CERIA), Hôpital Cochin, AP-HP, Paris, France. romain.coriat@cch.aphp.fr

ABSTRACT
Portal hypertension, the most important complication with cirrhosis of the liver, is a serious disease. Sorafenib, a tyrosine kinase inhibitor is validated in advanced hepatocellular carcinoma. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of our study was to determine the effect of sorafenib on portal venous flow and portosystemic collateral circulation in patients receiving sorafenib therapy for advanced hepatocellular carcinoma. Porto-collateral circulations were evaluated using a magnetic resonance technique prior sorafenib therapy, and at day 30. All patients under sorafenib therapy had a decrease in portal venous flow of at least 36%. In contrast, no specific change was observed in the azygos vein or the abdominal aorta. No portal venous flow modification was observed in the control group. Sorafenib is the first anti-angiogenic therapy to demonstrate a beneficial and reversible decrease of portal venous flow among cirrhotic patients.

Show MeSH
Related in: MedlinePlus